Skip to main content
. Author manuscript; available in PMC: 2019 Dec 25.
Published in final edited form as: J Am Coll Cardiol. 2018 Dec 25;72(25):3246–3254. doi: 10.1016/j.jacc.2018.09.076

Table 4.

Association between incident HF subtype and longitudinal change in galectin-3

HFpEF (63 events)
HFrEF (38 events)
Model HR (95% CI) P-value HR (95% CI) P-value
Age, sex, baseline Gal-3- adjusted 1.59 (1.18 - 2.13) 0.0022 1.73 (1.36 - 2.19) <0.0001
Multivariable- adjusted* 1.39 (1.05 - 1.84) 0.0212 1.42 (1.02 - 1.96) 0.03
*

Multivariable models adjusted for baseline galectin-3 levels, age, sex, systolic blood pressure, antihypertensive treatment, diabetes, body mass index, smoking, left ventricular hypertrophy, high-density lipoprotein (HDL) to cholesterol ratio, estimated glomerular filtration rate, prevalent cardiovascular disease (except for CVD model). Mortality analysis also adjusted for prevalent heart failure.

Hazard ratio and 95% confidence intervals for 1 standard devitaion (SD) increase in log-Gal3 levels over a 10-year period. This corresponds to 3.3 ng/ml change in Gal-3.